Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Highly sensitive and specific plasma biomarkers for Alzheimer’s disease (AD) have the potential to improve diagnostic accuracy in the clinic and facilitate research studies including enrollment in prevention and treatment trials. We recently reported CSF tau hyperphosphorylation, especially on T217, is an accurate predictor of β-amyloidosis at asymptomatic and symptomatic stages. In the current study, we determine by mass spectrometry the potential utility of plasma p-tau isoforms to detect AD pathology and investigate CSF and plasma tau isoforms’ profile relationships. Plasma tau was truncated as previously described in CSF. CSF and plasma measures of p-tau-217 and p-tau-181 were correlated. No correlation was found between CSF and plasma on total-tau levels and pS202 measures. We found p-tau-217 and p-tau-181 were highly specific for amyloid plaque pathology in the discovery cohort (n = 36, AUROC = 0.99 and 0.98 respectively). In the validation cohort (n = 92), p-tau-217 measures were still specific to amyloid status (AUROC = 0.92), and p-tau-181 measures were less specific (AUROC = 0.75).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Plasma tau measurement could thus be used as a screening test in early-stage clinical trials to enrich trial participation with individuals more likely to have AD pathology (76, 77, 90).”
From All the Tau We Cannot See (2023) · cites this paper as [76]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Like NfL (neurofilament light chain), plasma tau has emerged as a marker of neuronal distress. It appears in several different neurodegenerative diseases, including importantly even preclinical AD patients (76–85).”
From All the Tau We Cannot See (2023) · cites this paper as [76]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Plasma levels of p-tau are strongly associated with PET and CSF biomarkers of AD pathology19–25, neuropathological changes associated with AD20,23,26,27 and the subsequent development of AD dementia20,23,28.”
From Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests (2024) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CSF levels of Aβ and phosphorylated tau, as assessed by immunoassays, correlate with AD disease state and neurodegenerative pathology, but more disease specific information can be gleaned from assessment of the specific post-translational modifications of tau [37,59].”
From Evaluation of exploratory fluid biomarkers from a phase 1 senolytic trial in mild Alzheimer's disease (2025) · cites this paper as [37]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Self-citationHigh performance plasma amyloid-β biomarkers for Alzheimer's disease
Nakamura, A., Kaneko, N., Villemagne, V. L., Kato, T., Doecke, J., Doré, V., Fowler, C., Li, Q.-X., Martins, R., Rowe, C., et al. (2018) · Nature · doi:10.1038/nature25456 · Cited by 1,681
Janelidze, S., Mattsson, N., Palmqvist, S., Smith, R., Beach, T. G., Serrano, G. E., Chai, X., Proctor, N. K., Eichenlaub, U., Zetterberg, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0755-1 · Cited by 1,247
Dominantly Inherited Alzheimer Network, Preische, O., Schultz, S. A., Apel, A., Kuhle, J., Kaeser, S. A., Barro, C., Gräber, S., Kuder-Buletta, E., LaFougere, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0304-3 · Cited by 927
Self-citationRevisiting biomarker discovery by plasma proteomics
Geyer, P. E., Holdt, L. M., Teupser, D., & Mann, M. (2017) · Molecular Systems Biology · doi:10.15252/msb.20156297 · Cited by 917
Fagan, A. M., Roe, C. M., Xiong, C., Mintun, M. A., Morris, J. C., & Holtzman, D. M. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.noc60123 · Cited by 897
High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis
Schindler, S. E., Bollinger, J. G., Ovod, V., Mawuenyega, K. G., Li, Y., Gordon, B. A., Holtzman, D. M., Morris, J. C., Benzinger, T. L. S., Xiong, C., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000008081 · Cited by 885 · cited 4×
“…biomarker compared with its measurement in CSF. Blood plasma amyloid-β (Aβ) 42/40 ratio recapitulates with accuracy change on Aβ42/40 ratio detected in CSF and associates with measures of brain amyloid plaques by amyloid PET scans (Ovod et al., 2017; Nakamura et al., 2018; Schindler et al., 2019).”
BackgroundMethodInfluentialSelf-citationAdvancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) investigators, Thijssen, E. H., La Joie, R., Wolf, A., Strom, A., Wang, P., Iaccarino, L., Bourakova, V., Cobigo, Y., Heuer, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0762-2 · Cited by 761
the Dominantly Inherited Alzheimer Network, Barthélemy, N. R., Li, Y., Joseph-Mathurin, N., Gordon, B. A., Hassenstab, J., Benzinger, T. L. S., Buckles, V., Fagan, A. M., Perrin, R. J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0781-z · Cited by 651
Self-citationMielke, M. M., Hagen, C. E., Xu, J., Chai, X., Vemuri, P., Lowe, V. J., Airey, D. C., Knopman, D. S., Roberts, R. O., Machulda, M. M., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.013 · Cited by 621
Cited by
Items 401–476 of 476
Pietro, L. (2023) · New Medical Innovations and Research · doi:10.31579/2767-7370/051
Fluid-based biomarkers in neurodegeneration: Current findings and future directions
Blagojević, S., Jeremić, M., & Marković, I. (2024) · Medicinski podmladak · doi:10.5937/mp75-54180
“It allows for targeted protein quantification, through selected reaction monitoring or parallel reaction monitoring, for known biomarkers, but also leaves room for exploratory monitoring needed for new biomarker detection and proteomics research (88, 90, 91).”
Advances in fluid-based biomarkers
Zetterberg, H. (2025) · Elsevier eBooks · doi:10.1016/b978-0-12-822240-9.00008-9
Fluid and Imaging Markers of Amyloid Pathology
West, T., Meyer, M. R., Kirmess, K. M., Yarasheski, K. E., Braunstein, J. B., & Verghese, P. B. (2025) · Springer eBooks · doi:10.1007/978-3-031-80849-4_1
ROLE OF GENOMICS AND PROTEOMICS IN DISEASE DIAGNOSIS
Ali, M. A., Arfeen, Naeem, H., Munir, S., Nayab, S., Yousuf, F., Alvi, N., & Kalwar, A. (2025) · Journal of medical & health sciences review. · doi:10.62019/agyama54
Dauer, M. (2025) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-11427
Upadhyay, K. D., Viramgami, A., Singh, D., Kulkarni, N., Chudasama, B., Sivaperumal, P., & Balachandar, R. (2025) · Research Square · doi:10.21203/rs.3.rs-7788186/v1
Traub, J., Otto, M., Sell, R., Göpfert, D., Homola, G. A., Steinacker, P., Oeckl, P., Morbach, C., Frantz, S., Pham, M., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21311004
Guo, Z., Tian, C., Shi, Y., Song, X.-R., Yin, W., Tao, Q.-Q., Liu, J., Peng, G.-P., Wu, Z.-Y., Wang, Y.-J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26689169
Xiao, Z., Wu, X., Wu, W., Yi, J., Liang, X., Ding, S., Zheng, L., Luo, J., Gu, H., Zhao, Q., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14913836
Xiao, Z., Wu, X., Wu, W., Yi, J., Liang, X., Ding, S., Zheng, L., Luo, J., Gu, H., Zhao, Q., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14913830
Xiao, Z., Wu, X., Wu, W., Yi, J., Liang, X., Ding, S., Zheng, L., Luo, J., Gu, H., Zhao, Q., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14913827
Guo, Z., Tian, C., Shi, Y., Song, X.-R., Yin, W., Tao, Q.-Q., Liu, J., Peng, G.-P., Wu, Z.-Y., Wang, Y.-J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26689172
Miller, M. W., Wolf, E. J., Zhao, X., Logue, M. W., & Hawn, S. E. (2024) · Figshare · doi:10.6084/m9.figshare.26687882
Developing TomoNet: A Deep Learning Feature Extractor for Medical Image Classification
Guerra - Librero Camacho, J. (2023) · doi:10.11575/prism/41484
Miller, M. W., Wolf, E. J., Zhao, X., Logue, M. W., & Hawn, S. E. (2024) · Figshare · doi:10.6084/m9.figshare.26687885
Miller, M. W., Wolf, E. J., Zhao, X., Logue, M. W., & Hawn, S. E. (2024) · Figshare · doi:10.6084/m9.figshare.26687888
Bayoumy, S., Verberk, I. M. W., den Dulk, B., Hussainali, Z., Zwan, M. D., van der Flier, W. M., Ashton, N. J., Zetterberg, H., Blennow, K., Vanbrabant, J., et al. (2021) · Figshare · doi:10.6084/m9.figshare.17126153
Xiao, Z., Wu, X., Wu, W., Yi, J., Liang, X., Ding, S., Zheng, L., Luo, J., Gu, H., Zhao, Q., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14913824
Puig‐Pijoan, A. (2024) · Tesis Doctorals en Xarxa (Consorci de Serveis Universitaris de Catalunya)
Developing translational kinetic biomarkers for neurodegenerative disease
Leckey, C. A. (2023) · UCL Discovery (University College London)
Measuring White Matter Changes in Alzheimer’s Disease Using a Novel Technique
Bhargava, V., & Bhargava, V. (2024) · UA Campus Repository (The University of Arizona)
Emeršič, A. (2024) · Repository of the University of Ljubljana (University of Ljubljana)
Gerards, M. (2024) · Kölner Universitäts PublikationsServer (Universität zu Köln)
Compositie en maturatie van Tau aggregaten in de ziekte van Alzheimer
Gomes, L. (2021) · Lirias
Methods for Correlated Data: Large-scale Linear Mixed Models and Brain Connectivity Networks
Yue, K. (2024) · ResearchWorks at the University of Washington (University of Washington)
Ballvé, A. (2025) · Tesis Doctorals en Xarxa (Consorci de Serveis Universitaris de Catalunya)
Plasmaphosphorylated tau as biomarkers for multiple sclerosis diagnosis, subtyping, and prognosis
Hu, C., Zeng, X., Zhang, L., Sehrawat, A., Powell, M. M., Song, E., Walker, E., Watterson, A., Zhu, W., Karikari, T. K., et al. (2025) · Brain Communications · doi:10.1093/braincomms/fcaf510 · Cited by 1
“25 In contrast, p-tau biomarkers (e.g. p-tau181 and p-tau217) are thought to reflect the same pool of brain-secreted p-tau as in CSF. 71 These biomarkers have consistently demonstrated superior performance, showing strong correlation with CSF p-tau and tau PET imaging, tracking with disease stage…”
InfluentialBlood-based emerging biomarkers in early detection and diagnosis of Alzheimer’s disease
Anand, T., & Kumar, A. (2026) · International review of neurobiology · doi:10.1016/bs.irn.2026.01.002
Machine learning algorithms for plasma AD biomarkers implementation in two real-world cohortsPreprint
Torrigiani, E. G., Bellomo, G., Cianca, D., Nardi, G., Neri, I., Chiasserini, D., Agnello, L., Ciaccio, M., Piccoli, T., Parnetti, L., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-8987177/v1
Priya, Mittal, R., Banerjee, J., & Dixit, A. B. (2026) · International review of neurobiology · doi:10.1016/bs.irn.2026.02.006
Tau-proteiinin mittaaminen verestä neurodegeneratiivisissa sairauksissa
Pääkkö, J. (2026) · UTUPub (University of Turku)
Signatures épigénétiques de la maladie d'Alzheimer dans l'ADN libre circulant
Guemri, J. (2021) · theses.fr (ABES) · doi:10.70675/aa3cb199zc068z4b72zab7fz6deb0fe1de87
Dautricourt, S. (2021) · theses.fr (ABES) · doi:10.70675/63472a25z31eaz4ebczaebdzd8d2e061b4b8
Van, K. T. (2025) · theses.fr (ABES) · doi:10.70675/32a1a6cez5dd3z42c0za2eaz2e57807081a6
Atypical involvement of Alzheimer’s tau proteins in diseases beyond tauopathies
Meng, J., Deng, Z., Zhang, J., Yu, W., Wu, X., & Lei, P. (2026) · Life Medicine · doi:10.1093/lifemedi/lnag016
Palin, T., Corbett, J., Hill, L. J., Woods, D. R., Gould, A. A. M., Wainwright, B. G., Roberts, J. A., Thomas, C. N., Snape, D., House, C., et al. (2026) · Experimental Physiology · doi:10.1113/ep093598
Quantum-enhanced biosensing for early detection of neurodegenerative disorders
Musa, I. O., Livinus, M. U., Abdulsalam, M., Aremu, S. O., Bala, S. Z., Hassan, M., Sani, S., Samuel, J. O., Mustapha, A., Peter, A. O., et al. (2026) · Journal of Clinical and Translational Research · doi:10.36922/jctr025440076
The Tau-mitochondria connection and its impact on cellular energy metabolism in Alzheimer’s disease
Singh, A. K., Supraja, M. R., Amal, P. S., Krishnamoorthi, S., Iyaswamy, A., & Durairajan, S. S. K. (2026) · International review of neurobiology · doi:10.1016/bs.irn.2026.06.002
Sindhu, M. A. (2026) · Health & Medical Sciences · doi:10.47134/phms.v3i4.678
Exploring longitudinal relationships among Alzheimer's disease biomarkers
Saef, B. A., Petersen, K. K., Volluz, K., Li, Y., Tosun, D., Milà‐Alomà, M., Shaw, L. M. J., Zetterberg, H., Dage, J. L., Rubel, C. E., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71711
Predicting continuous amyloid PET levels with CSF and plasma brain‐derived p‐tau217
Trudel, L., Therriault, J., Macedo, A. C., Aumont, É., Hosseini, S. A., Benedet, A. L., Hazrati, L., Gauthier, S. G., Zetterberg, H., Vitali, P., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71723
“12,13,30 At higher levels of A β burden, plasma and CSF p-tau217valuesappearedtoplateau,resultinginreduceddynamicrange despite persistently elevated biomarker levels.”
Plasma Biomarkers Differentiate Cognitive Impairment in Postmenopausal Women with Insomnia Disorder
Wang, D., Chen, B., Jin, K., Cheng, S., Qin, B., Tian, Y., Lü, J., & Chu, K. (2026) · Psychiatry and Clinical Psychopharmacology · doi:10.65801/pcp.3463
“85 In the present study, we observed that plasma p-Tau levels were significantly elevated in postmenopausal women with insomnia disorder who met criteria for cognitive impairment, whereas t-Tau levels did not differ between groups.”
Czech, J., Weyland, C. S., Neumann, M., Drzezga, A. E., & Schulz, J. B. (2026) · Springer eBooks · doi:10.1007/978-3-032-13040-2_6
Chen, Y., Zhang, L., Chen, N., Han, Y., & Lang, G.-P. (2026) · Journal of Clinical Insight · doi:10.1016/j.jci.2026.100008
Silent clues in blood: Proteomic approach for Alzheimer’s disease
da Silva, A. R. V., da Conceição, R. S. V., Medeiros, C. M. D. S., Sousa, M. D. S., de Jesus, J. R., & Júnior, C. A. L. (2026) · International review of neurobiology · doi:10.1016/bs.irn.2026.08.009
Decoding disease progression: Biomarker in Alzheimer’s and Parkinson’s disease
Paul, S., Rai, S., & Kumar, S. (2026) · Advances in pharmacology · doi:10.1016/bs.apha.2026.04.001
Merino, J. J., Rodriguez, J. J., Busquets, X., Flores, A. I., & Tolédano, A. (2026) · Life · doi:10.3390/life16091554
Wang, J., Li, Z., Wang, T., Jiang, L., Sharif, A., Takechi, R., Li, T., Chong, L. H., Fang, F., Pang, Z., et al. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.09.013
Fernández, A., Molanes-lopez, E. M., Zuluaga, P., Vaquero, L., Moldenhauer, F., Galván-Román, J., Bajo, R., Lagunas, N., & Alba, J. G. (2026) · Journal of Neurology · doi:10.1007/s00415-026-14165-6
“This evolution of p-tau217 is consistent with its role as a specific biomarker of AD pathology, reflecting the pathological accumulation of phosphorylated tau in the brain [33–35].”
Özdüzenciler, P., Müller, L., Kara, E., Weber, M.-C., Pils, M., Rehn, F., Bannach, O., Fink, G. R., Willbold, D., Barbe, M. T., et al. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-026-02188-0
Schwartz, N. U., Ellingson, T. N., Nguyen, H., Lin, Z., Ashton, N. J., Dage, J. L., Deniz, K., Dietz, C. D., Ljubenkov, P. A., Miller, B. L., et al. (2026) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70446
Quadrini, K. J., Aubrecht, J., Vernhes, F., Zeng, X., Johnson, A. D., Snitz, B. E., Cohen, A. D., Tooker, R. E., Quiceno, M. E., Campbell, B. M., et al. (2026) · medRxiv · doi:10.64898/2026.09.28.26363900
Quantitative Relationship Between Lumipulse G Measures of pTau217 in Plasma and the Temporal Cortex
Meyer, S. D., Tomé, S. O., Lahaije, B., Vanbrabant, J., Lambrechts, C., Goossens, J., Vanmechelen, E., Sleegers, K., Arnim, C. A. F. V., Tousseyn, T., et al. (2026) · Neurology · doi:10.1212/wnl.0000000000218598
“34,35 Both the pTau217 NT and the pTau217 Mid assay therefore detect C-terminally truncated forms of pTau217.”
The role of neurofilament light chain and other fluid biomarkers in cerebellar ataxias
Mouraux, C., Santana, M. M., Rosenthal, L. S., Cortese, A., Santorelli, F. M., Opal, P., & Coarelli, G. (2026) · Brain Communications · doi:10.1093/braincomms/fcag313
“88,89 Consequently, plasma t-tau may be more relevant in acute CNS injuries than in chronic, slowly progressive diseases, such as inherited ataxias.”
Elder, N., Nguyen, H., 완자손, Johnson, T. P., Lee, M., Ng, C., Yokoyama, J. S., & Lin, R. (2026) · Scientific Reports · doi:10.1038/s41598-026-74727-6
Stubs, J., Langballe, E. M., Livingston, G., Anstey, K. J., Deckers, K., Kivimäki, M., Strand, B. H., Sunde, A. L., Zetterberg, H., & Selbæk, G. (2026) · medRxiv · doi:10.64898/2026.10.15.26365615
Abdelaziz, G., Abdel-Ghaffar, A.-R. B., Amr, D., Nada, A. M. K., & Gabre, R. M. (2026) · Scientific Reports · doi:10.1038/s41598-026-71629-5
Qi, Y., Miller, L. R., D'Ascenzo, M. D., Berndt, J. D., Whitney, G. A., Duffy, F. J., Danziger, S. A., Peskind, E. R., Li, G., Masters, C. L., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-74186-z
Brain-derived tau in plasma and cerebrospinal fluid after surgery: a prospective cohort substudy
Thorsson, M., Eriksson, L. I., Danielson, M., Wiklund, A., Hergès, H. O., Nellgård, B., Zetterberg, H., Schening, A., Granström, A., Ricksten, S., et al. (2026) · British Journal of Anaesthesia · doi:10.1016/j.bja.2026.08.055
Rao, Y., Liu, L., Ostaszewski, B. L., Anderson, A. K., Pinilla, V., Shirzadi, Z., Laho, E. M., Stern, A. M., Yau, W. W., Yang, H., et al. (2026) · Neurology · doi:10.1212/wnl.0000000000218564
Serum p-tau181 and p-tau217 levels in adolescents and adults with 5q spinal muscular atrophy
Stapf, C. D., Uzelac, Ž., Iterbeke, L., Guthknecht, A., Barba, L., Strube, D., Kölsch, A., Kleeberg, K., Kendzierski, T., Roos, A., et al. (2026) · Journal of Neurology · doi:10.1007/s00415-026-14194-1
Okada, K., Shimohama, S., Okochi, R., Bun, S., Takahata, K., Tabuchi, H., Iwabuchi, Y., Tezuka, T., Nukariya, T., Okusa, S., et al. (2026) · medRxiv · doi:10.64898/2026.10.19.26365782
Design of readers for pathological PTM proteoforms in Alzheimer’s diseasePreprint
Wu, K., Schantz, T., Chang, L., Chabria, P., Bashaw, E., Kalatturu, T. R., Kim, D. Y., Chen, A., Corley, N., Bera, A. K., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.20.760520
“Phospho-Tau species, particularly pT217 and pT231, are important AD biomarkers [11–14], and detecting multiple phosphorylation sites on individual molecules can improve diagnostic discrimination [17].”
APOE ε4 accelerates plasma p-tau217 trajectory: a Bayesian joint longitudinal analysis of ADNI
Chu, K.-Y. (2026) · Neurological Sciences · doi:10.1007/s10072-026-09435-0
“Most published work on these biomarkers is cross-sectional; the few longitudinal studies [21, 22] have not tested discrete trajectory sub-groups versus continuous heterogeneity, used per-participant slopes as prognostic predictors, or jointly evaluated GFAP and p-tau217 against APOE ε4.”
Sadleir, K. R. (2025) · Galter Health Sciences Library, Northwestern University · doi:10.18131/0m0ef-phj22
BindingDB (2024) · UC San Diego · doi:10.7270/q2hq44b5
Internship Report and Monograph entitled “Alzheimer's Disease in Individuals with Down Syndrome”.
Rodrigues, B. S. A. (2021) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Maryam, & Mohiuddin, A. H. (2026) · The Open Biomarkers Journal · doi:10.2174/0118753183505770261022105834
A Hybrid Fluorescence-Optoelectronic Nanoscale Sensor for the Early Diagnosis of Tau Pathology
Mandal, S. M., Hoque, M. E., Bandaru, P. R., & Ghosh, G. (2026) · ACS Sensors · doi:10.1021/acssensors.6c00511
Modular nanoplatforms for precision diagnosis and therapy of Alzheimer's disease
Yan, M., Tian, L., & Gao, W. (2026) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2026.103047
Supporting information 2 of Diagnostic Accuracy of Blood-Based Biomarker Panels: A Systematic Review
Hardy-Sosa, A., León-Arcia, K., Llibre-Guerra, J. J., Berlanga-Acosta, J., Baez, S. D. L. C., Guillen-Nieto, G., & Valdes-Sosa, P. A. (2022) · doi:10.3389/fnagi.2022.683689.s002
Javonillo, D. I., Tran, K. M., Phan, J., Hingco, E., Kramár, E. A., da Cunha, C., Forner, S., Kawauchi, S., Milinkeviciute, G., Gomez-Arboledas, A., et al. (2022) · doi:10.3389/fnins.2021.785276.s001
Xin, J.-Y., Huang, X., Sun, Y., Jiang, H.-S., Fan, J., Yu, N.-W., Guo, F.-Q., Ye, F., Xiao, J., Le, W.-D., et al. (2022) · doi:10.3389/fnagi.2022.838223.s003
Metadata
- Authors
- Barthélemy, N. R., Horie, K., Sato, C., & Bateman, R. J.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Barthélemy, Nicolas R.
- Bateman, Randall J.
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2020-07-28
- Volume
- 217
- Issue
- 11
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC7596823
- OpenAlex
- W3045987239
- Cited by
- 437
- References
- 36
- Citations by year
- 2026: 57 · 2025: 72 · 2024: 72 · 2023: 64 · 2022: 82 · 2021: 71 · 2020: 19
- FWCI
- 35.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Experimental Medicine (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by-nc-sa)
- Funders
- Alzheimer’s Association (AARF-16-443265)
- Rainwater Charitable Foundation
- National Institutes of Health
- National Institute of Neurological Disorders and Stroke (R01NS095773)
- Tau SILK Consortium
- AbbVie
- Biogen
- Eli Lilly and Company
- Coins for Alzheimer’s Research Trust
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- Alzheimer's disease, tau isoforms, CSF tau, plasma biomarkers, amyloid plaques, beta-amyloidosis, diagnostic accuracy, tau truncation
- MeSH terms
- Adult, Aged, Aged, 80 and over, Alzheimer Disease, Brain, Female, Humans, Male, Middle Aged, Phosphorylation, Mass Spectrometry, Cohort Studies, Biomarkers, Case-Control Studies, Amyloid beta-Peptides, tau Proteins, Protein Isoforms, Positron-Emission Tomography, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.